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Background: Channeling bias may occur when a newly marketed drug and an established drug, 
despite similar indications, are prescribed to patients with different prognostic characteristics 
(ie, confounding).
Aim: To investigate channeling bias and its impact on relative effectiveness of glucagon-like 
peptide-1 (GLP-1) analogs versus basal insulin and dipeptidyl peptidase-4 inhibitors (DPP-4i) 
versus sulfonylurea.
Methods: In the UK Clinical Practice Research Datalink, patients with type 2 diabetes initiating 
treatment between 2006 and 2015 were included. Analyses were stratified by years since first 
prescription of GLP-1 and DPP-4i, respectively. The characteristics of GLP-1 versus insulin and 
DPP-4i versus sulfonylurea initiators were compared over time. After propensity score match-
ing, the relative effectiveness regarding 6-month changes in glycated hemoglobin (HbA
1c
) and 
body weight was estimated.
Results: In total, 8,398 GLP-1, 14,807 insulin, 24,481 DPP-4i, and 33,505 sulfonylurea initia-
tors were identified. No major channeling was observed. Considerable overlap in distributions 
of characteristics allowed for propensity score-matched analyses. Relative effectiveness was 
similar across time. The overall relative effect of GLP-1 versus insulin showed no difference 
for HbA
1c
 and relative increase in body weight (3.57 kg [95% confidence interval {CI}: 3.21, 
3.92]) for insulin. The overall relative effect of DPP-4i versus sulfonylurea showed relative 
decrease in HbA
1c
 (–0.34% [95% CI: –0.38, –0.30]) and increase in body weight (1.58 kg [95% 
CI: 1.38, 1.78]) for sulfonylurea.
Conclusion: No major channeling was identified in the investigated glucose-lowering drugs. 
Relative effectiveness could be estimated already in the first year after launch and was consistent 
in the years thereafter.
Keywords: channelling bias, channeling bias, glucose-lowering drugs, DPP-4i, GLP-1, type 2 
diabetes, observational study, relative effectiveness
Introduction
Randomized controlled trials are primarily designed and conducted to meet the needs 
of regulatory bodies, so as to provide evidence on the efficacy and the safety of new 
drugs or other health care interventions. However, these studies are generally insuf-
ficient by themselves to meet the evidentiary needs of many health technology assess-
ment  agencies, that is, evidence on the drug’s effectiveness. Similarly, clinicians and 
payers desire evidence on comparative effectiveness of new drugs immediately after 
launch to take informed decisions.1 The sooner valid comparative effectiveness research 
results can be generated, the more useful they are to patients, clinicians, and payers. 
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 Comparative effectiveness research using secondary health 
care data (including electronic medical records, longitudinal 
claims data, and registries) provides evidence on the benefits 
and risks of drugs in routine medical practice.1 However, 
channeling bias is a potential risk when relative effectiveness 
of a newly marketed drug compared to an established drug 
is investigated in observational data.
Channeling bias may occur when a newly marketed drug 
and an established drug, despite similar therapeutic indica-
tions, are prescribed to patients with different prognostics 
characteristics.2 Over time, the prognostic characteristics 
of the patients who prescribed the two drugs may become 
more balanced as the newly marketed drug becomes more 
established. Reasons for channeling bias could be a belief 
in extra advantages of the new drug compared to the estab-
lished drug, or simply because doctors do not know how 
else to treat a subgroup of patients due to intolerance or low 
response to established drugs. It is possible that patients 
with a better prognostic are channeled to the newly marketed 
drug, but it is often theorized that a newly marketed drug is 
predominantly prescribed to patients with worse prognostics 
compared to the established drug being prescribed to patients 
with better prognostics.1,2 When channeling bias occurs, com-
parative effectiveness research becomes challenging because 
 comparison with a drug will be confounded and knowledge 
of comparative effectiveness close to market entry may be 
biased or absent.
The first glucagon-like peptide-1 analogs (GLP-1), 
exenatide, was approved by the European Medicines Agency 
(EMA) in November 2006, and the first dipeptidyl pepti-
dase-4 inhibitor (DPP-4i), sitagliptin, was approved by the 
EMA in March 2007. A US study on prescription pattern of 
exenatide during the first half year after approval showed that 
a higher proportion of obese patients used exenatide com-
pared to patients with other glucose-lowering drugs, indicat-
ing an awareness of weight-lowering effects of GLP-1.3 Three 
US studies4–6 compared the characteristics of sitagliptin users 
with patient receiving other oral glucose-lowering drugs; two 
of the studies4,5 compared 2006–2007 versus 2008–2010, and 
the third study6 investigated the first 2½ years after approval 
of sitagliptin. The three studies4–6 found that DPP-4i users 
were older and have more comorbidities than patients receiv-
ing other oral glucose-lowering drugs, but with no change 
over time. These studies3–6 were all descriptive and did not 
investigate if the differences in characteristics could be taken 
into account in an outcome analysis.
The objectives of this study were, first, to compare the 
characteristics of patients initiating GLP-1 to those  initiating 
basal insulin and of patients initiating DPP-4i to those initiat-
ing sulfonylurea stratified on calendar time and, second, to 
assess the relative effectiveness over time since the market 
entry of GLP-1 and DPP-4i.
Methods
The United Kingdom Clinical Practice Research Datalink 
(CPRD) was used for this study. The CPRD is derived from 
UK primary care and holds longitudinal patient-level data 
such as diagnoses, mortality, laboratory results, and pre-
scription data. It is the representative for the UK general 
population, and validation ensures high-quality data.7–10 
Anonymized data are available after protocol approval from 
the Independent Scientific Advisory Committee (ISAC).11
For this study, data about patients aged ≥18 years with a 
diagnosis of type 2 diabetes and a prescription of glucose-
lowering medication between January 1, 2006, and February 
9, 2015, were extracted. Validation studies have shown that 
diagnosis of type 2 diabetes alone is not always correct, so 
to ensure identification of patients with type 2 diabetes, 
patients were included if they fulfilled one of the following 
criteria:12 1) first diagnosis (either type 1 or type 2) before 
age 35 years and no continual insulin treatment within six 
months of diagnosis, or 2) first diagnosis (either type 1 or 
type 2) after age 35 years and not on continual insulin treat-
ment from diagnosis.
Exposure, cohorts, and time blocks
Two comparison groups were used throughout the study; 
initiators of GLP-1 were compared with initiators of basal 
insulin, whereas initiators of DPP-4i were compared with 
initiators of sulfonylurea. The chosen comparator groups 
were to compare second-line (DPP-4i and sulfonylurea) and 
third-line (GLP-1 and insulin) treatments, respectively.13 
The glucose-lowering drugs were handled at the drug-class 
level, and combination products of metformin and DPP-4i 
and of rosiglitazone and sulfonylurea were considered as 
DPP-4i and sulfonylurea. Prescriptions of drugs were used 
to identify episodes of treatment. For each patient, the end 
of a prescription was estimated from the daily dose and 
amount prescribed (typically available for GLP-1, DPP-4i, 
and sulfonylurea), or as the patient’s median duration of 
prescription of the drug (typically the case for insulin). If 
there were <120 days between the estimated end date of 
one prescription and the start date of the next prescription, 
the prescriptions were considered to make up a continuous 
episode of drug treatment. Initiation was defined as patients 
with a prescription of one of the four glucose-lowering 
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drugs after minimum 180 days without a prescription of 
the drug (washout period). Two cohorts were created, by 
analogy with the terms used in clinical trials: the intention-
to-treat (ITT) cohorts comprise subjects with a treatment 
duration of at least one day, whereas the per-protocol (PP) 
cohorts comprise subjects with a  treatment duration of at 
least 180 days. Patients could appear on both the ITT and 
the PP cohorts. With the two comparisons, this makes up 
four cohorts in total. If patients were identified as incident 
users more than one time for the same drug, only the first 
initiation was considered. If patients initiated GLP-1 and 
insulin, or DPP-4i and sulfonylurea at the same time, this 
initiation was censored. Within each of the four cohorts, 
time blocks of 365-day duration were defined with start 
date of the first initiation of GLP-1 or DPP-4i, respectively. 
If patient initiated the comparison drugs within the same 
time block, only the first initiation was used and the second 
initiation was censored.
Outcome
Measures of glycated hemoglobin (HbA
1c
) and body weight 
were used to establish outcome measures. The goal was 
to observe change in HbA
1c
 and in body weight during a 
180-day period. However, because measurements were not 
always available at the exact date of treatment initiation 
and 180 days after initiation, the following were deployed 
when measurements were not available: If a measurement 
was available within 90 days prior to initiation, this was 
used as the measurement at initiation, and if a measurement 
was available between 90 and 179 days after initiation, this 
was used as the measurement 180 days after initiation. If 
several measurements were available within these periods, 
the measurement closest to the initiation date and 180 days 
after initiation, respectively, was used.
Covariates
The following covariates were used: sex; age at initiation; 
weight at initiation; body mass index (BMI) at initiation; 
HbA
1c
 at initiation; duration of diabetes at initiation; num-
ber of oral glucose-lowering drugs at initiation; any use of 
glucose-lowering drugs (sulfonylurea, basal insulin, DPP-4i, 
metformin, and other oral glucose-lowering drugs) during 
the washout period; any use of antihypertensive, statins, 
and anticoagulants during the washout period; Charlson 
 Comorbidity Index14 at initiation; and any diagnosis of 
hypertension, end-stage renal disease, myocardial infarc-
tion, or stroke prior to initiation. The covariate number of 
oral glucose-lowering drugs at index was a count of pre-
scriptions at index of any of the following glucose-lowering 
drugs; acarbose, canagliflozin, canagliflozin combined with 
metformin, dapagliflozin, dapagliflozin combined with met-
formin, empagliflozin, pioglitazone, pioglitazone combined 
with metformin, rosiglitazone, rosiglitazone combined with 
metformin, nateglinide, repaglinide, troglitazone, guar gum 
and metformin in the comparison of DPP-4i and sulfonylurea, 
and in the comparison of GLP-1 and basal insulin number 
of other oral glucose-lowering drugs at index also included 
DPP-4i and sulfonylurea. The covariate other oral glucose-
lowering drugs during washout was a binary response if at 
least one of the following glucose lowering drugs were pre-
scribed during the washout period; acarbose, canagliflozin, 
canagliflozin combined with metformin, dapagliflozin, 
dapagliflozin combined with metformin, empagliflozin, 
pioglitazone, pioglitazone combined with metformin, rosigli-
tazone, rosiglitazone combined with metformin, nateglinide, 
repaglinide, troglitazone or guar gum.
Missing data
Information on HbA
1c
, BMI, weight, and diabetes duration 
was missing for some individuals. Under the assumption 
that these missing data were missing at random, missing 
values were imputed. Multiple imputation was applied, 
with 10 imputed datasets.15 In addition to imputation of 
missing measurements at initiation, missing measurements 
180 days after initiation were also imputed.16 We used the 
listed covariates, treatment group and change in HbA1c and 
weight for the imputation. The Charlson comorbidity index 
was categorized into four groups: 0–1, 2, 3, and more than 3 
points. Number of OADs was categorized into four groups: 0 
OADs, 1 OADs, 2 OADs, 3 OADs, and more than 3 OADs. 
Results for both the descriptive and the outcome analyses 
were pooled across the imputed datasets using Rubin’s rule.17 
Post hoc we noticed that a fraction of HbA1c measurements 
was very low for GLP-1 and insulin initiators, and that most 
of these measurements were located around the fourth year 
since GLP-1 approval. As we suspected these measurements 
were incorrect, all HbA1c measurements below 4% were 
treated as missing and were imputed as described above.
Propensity score and matching
Propensity scores were estimated as the probability of initiat-
ing GLP-1 in the comparison of GLP-1 and insulin initiators 
and the probability of initiating DPP-4i in the comparison 
of DPP-4i and sulfonylurea initiators. The propensity score 
models included the covariates mentioned earlier, except 
the covariate describing use of the comparison drug during 
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washout. These variables were not included because they 
were collinear with the initiated drug. Standardized difference 
was used to assess balance on covariates and to select the 
appropriate propensity score model.18 The propensity score 
was estimated twice: in the whole cohort for the descriptive 
purpose of characteristics over time and in the subgroup 
that did not receive the comparison drug during washout to 
be used for matching in the outcome analyses. Based on the 
propensity score, patients were matched in order to create 
treatment groups that were comparable with respect to the 
propensity score and thus the potential confounders. Greedy 
matching was done in a 1:1 ratio, stratified by time block 
and within each imputed dataset. The greedy matching was 
done in up to eight iterations; first the data were searched for 
matches based on eight digits of the propensity score, then 
seven digits, and continued to matches according to one digit 
(see Parson19 for details).
Descriptive analyses: characteristics 
over time
To assess changes in patient characteristics over time, the 
covariates and propensity score were plotted stratified by time 
blocks and treatment groups. This shows both general dif-
ferences between treatment groups and potential channeling, 
where characteristics change over time. The propensity score 
serves as a single variable to describe differences in charac-
teristics across comparison groups. Both the propensity score 
for all individuals and the propensity score for individuals 
suitable for matching (without use of the comparison drug 
during washout) were assessed. This was done in both the 
ITT and the PP cohorts. Because of the many covariates avail-
able, only the propensity score over time will be shown in the 
Result section, whereas graphs for each individual variable 
can be found in the supplementary material.
Outcome analyses: relative effect 
estimates over time
In the subgroup of the PP cohort that did not receive the com-
parison drug during washout, linear regression analyses were 
used to estimate the relative effect regarding change in HbA
1c
 
and change in body weight after 180 days of follow-up. Again, 
the comparison groups were GLP-1 versus basal insulin and 
DPP-4i versus sulfonylurea. These analyses were stratified 
by time blocks. Crude analyses were performed based on all 
identified initiators, in addition to analyses of the propensity 
score-matched initiators, to take confounding into account. 
In the analyses of change in HbA
1c
 and body weight, baseline 
levels of HbA
1c
 and body weight, respectively, were included 
as covariates in the outcome model.20 The relative effect esti-
mate and their 95% confidence intervals (CIs) were plotted for 
graphical inspections of changes in effect estimates over time.
SAS software 9.4 was used to carry out analyses. Data 
management was done using template programs developed 
by the department of epidemiology at Novo Nordisk for 
importing CPRD data into SAS format. Access to CPRD 
data was gained through approval of protocol by the ISAC 
(https://www.cprd.com/isac/). 
Results
In total, 304,953 patients with diabetes and a prescription of 
a glucose-lowering drug were identified. The first initiation 
of GLP-1 was observed on June 14, 2007, whereas the first 
initiation of DPP-4i was observed on June 22, 2007. For 
the descriptive analyses of characteristics over time, 10,633 
and 19,243 initiators of GLP-1 and insulin, respectively, and 
30,048 and 41,346 initiators of DPP-4i and sulfonylurea, 
respectively, were included in the ITT cohorts. The numbers 
of individuals in the PP cohorts were a little smaller. For the 
outcome analyses, 8,398 and 13,286 initiators of GLP-1 and 
insulin, respectively, and 10,847 and 30,643 initiators of 
DPP-4i and sulfonylurea, respectively, were identified. The 
exact number of propensity score-matched individuals var-
ies within each imputed dataset, but within each time block 
nearly half of the initiators of GLP-1 were matched with an 
initiator of insulin and nearly all initiators of DPP-4i were 
matched with an initiator of sulfonylurea. It was possible 
to create seven time blocks of 365 days in both the GLP-1 
and insulin, and the DPP-4i and sulfonylurea comparisons. 
Figure S1 provides a full flowchart detailing this.
Trends over time
The distributions of propensity score look similar for both 
the ITT and PP cohorts of all identified initiators of GLP-1 
and insulin, and DPP-4i and sulfonylurea, respectively, and 
also for the PP cohort of initiators with no use of the com-
parison drug during washout, which is the subgroup used 
for propensity score matching. Time blocks 1–7 are demon-
strated as histograms of the propensity score of the latter in 
Figures 1 and 2. Other propensity score plots are found in the 
 supplementary material Figure S2. In general, the distribu-
tion of propensity score of the GLP-1 and insulin initiators 
indicate an overlap in propensity score for all time blocks 
considered. The propensity score of DPP-4i and sulfonylurea 
initiators has an even greater overlap in all time blocks, and 
for both DPP-4i and sulfonylurea, the distribution moves 
from being centered on lower propensity scores in the early 
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Figure 1 Propensity score over time for GLP-1 versus basal insulin initiators. 
Notes: Blue: GLP-1, red: insulin.
Abbreviation: GLP-1, glucagon-like peptide-1 analogs.
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Figure 2 Propensity score over time for DPP-4i versus sulfonylurea initiators. 
Notes: Blue: DPP-4i, red: insulin.
Abbreviation: DPP-4i, dipeptidyl peptidase-4 inhibitors.
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Figure 3 Relative mean difference in change in HbA1C and weight (95% CI), GLP-1 (reference group) versus basal insulin initiator in the PP cohort adjusted for baseline 
HbA1c and weight, respectively. 
Notes: Gray: crude analyses, black: propensity score-matched patients. (A) HbA1c. (B) weight.
Abbreviations: CI, confidence interval; GLP-1, glucagon-like peptide 1 analogs; HbA1c, glycated hemoglobin; PP, per-protocol.
time blocks to being centered on 0.4 in later time blocks, 
which indicate comparable patients with a similar change 
in characteristics over time.
Figures of the individual covariates are found in 
 Figure S3–S4. In general, trends for the ITT and PP cohort 
were similar. Hence, there will be no distinction of the ITT 
and PP cohort in the following text. For initiators of GLP-1 
and insulin, minor changes in HbA
1c
 at initiation were 
observed; however, all were within the range of 0.5%. Both 
GLP-1 and insulin initiators had an increase in use of DPP-4i 
during washout and a decrease in use of other oral glucose-
lowering drugs during washout. For insulin initiators only, 
an increase in use of sulfonylurea, GLP-1, and metformin 
during washout was seen. Plots of the individual covariates 
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Figure 4 Relative mean difference in change in HbA1C and weight (95% CI), DPP-4i (reference group) versus sulfonylurea initiator in the PP cohort adjusted for baseline 
HbA1c and weight, respectively. 
Notes: Gray: crude analyses, black: propensity score-matched patients. (A) HbA1c. (B) weight.
Abbreviations: CI, confidence interval; DPP-4i, dipeptidyl peptidase-4 inhibitors; HbA1c, glycated hemoglobin; PP, per-protocol. 
also show some general differences of the comparison groups 
across time. Compared to initiators of insulin, the initiators of 
GLP-1 tended to have higher BMI; more number of glucose-
lowering drugs at initiation; increased use of metformin, other 
glucose-lowering drugs, DPP-4i, and statins during washout, 
increased proportion of with hypertension diagnoses; lower 
age; higher Charlson Comorbidity Index, increased propor-
tion of myocardial infarction and end-stage renal disease 
diagnoses; and shorter duration of diabetes.
For DPP-4i and sulfonylurea initiators, the plots of the 
individual covariates showed that initiators of both drugs 
had an increase in duration of diabetes and use of metformin 
during washout and a decrease in other oral glucose-lowering 
drugs during washout. For sulfonylurea initiators only, a 
minor increase in HbA
1c
 at initiation and an increase in use 
of DPP-4i and GLP-1 during washout were seen. Across the 
different time blocks, the initiators of DPP-4i, compared to 
initiators of sulfonylurea, tended to have higher BMI, more 
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prevalent use of other glucose-lowering drugs and statins dur-
ing washout, longer duration of diabetes, lower HbA
1c
, and, 
in the late time blocks, higher Charlson Comorbidity Index.
Outcome analyses
The considerable overlap in propensity scores allowed for 
propensity score matching and thus propensity score-matched 
relative effectiveness estimation. Standardized differences 
suggested balanced comparison groups after matching 
(Tables S1–S2).
Figure 3A and 3B shows the difference in change in HbA
1c
 
and body weight, respectively, for the comparison of GLP-1 
and insulin; nonsignificant differences in change in HbA
1c
, 
except from a peak in time block 4, and a relative increase 
in body weight for the insulin initiators compared to GLP-1 
initiators in all time blocks were seen. Across time blocks, 
the relative increase in body weight was 3.57 kg (95% CI: 
3.21, 3.92) for insulin initiators. Similarly, Figure 4A and 4B 
shows the difference in change in HbA
1c
 and body weight, 
respectively compared to DPP-4i and sulfonylurea; a rela-
tive decrease in HbA
1c
 and a relative increase in body weight 
for sulfonylurea initiators compared to DPP-4i  initiators in 
all time blocks were seen. Across time blocks, the relative 
decrease in HbA
1c
 was –0.34% (95% CI: –0.38, –0.30) and 
the relative increase in body weight was 1.58 kg (95% CI: 
1.38, 1.78) for sulfonylurea initiators.
Discussion
In this study, change in characteristics over time since begin-
ning treatment with GLP-1 and DPP-4i in  comparison with 
basal insulin and sulfonylurea, respectively, was  investigated 
with focus on potential channeling bias. Propensity score 
matching was applied to assess the relative effect on change 
in HbA
1c
 and weight. Channeling bias was not seen in the 
sense that the characteristics of GLP-1 and DPP-4i initiators 
changed over time after market entry, whereas the charac-
teristics of the initiators of the established drugs, insulin 
and sulfonylurea, were stable. Distribution of  propensity 
scores, used as an overall measure of differences in charac-
teristics, showed that initiators of GLP-1 and insulin were 
somewhat different, although with a substantial overlap, in 
all time blocks. Initiators of DPP-4i and sulfonylurea were 
more comparable with an even greater overlap across time 
blocks and with a similar change in propensity scores over 
time. For the individual covariates, changes in characteristics 
were observed in both groups of GLP-1 and insulin initia-
tors, and among DPP-4i and sulfonylurea initiators, as well 
as among initiators of insulin or sulfonylurea only.
There was sufficient overlap in distribution of charac-
teristics so that propensity score matching was possible to 
conduct relative effectiveness analysis, even in the first year 
after launch. The outcome analyses suggest similar change 
in HbA
1c
 for GLP-1 and insulin, except for the peak in time 
block 4. Overall, we consider this peak as a result of random 
variation given the absence of a difference in effects in the 
other time blocks. Insulin leads to weight gain compared to 
GLP-1 across time. The outcome analyses suggest a greater 
reduction in HbA
1c
 and weight gain for sulfonylurea com-
pared to DPP-4i.
It is hypothesized that patients initiating a newly launched 
drug are those most ill and with more use of comedications, 
but such differences will disappear over time when the 
new drug becomes more established.1,2 In this study, such 
a time trend was not observed. Also, it is hypothesized that 
patients initiating a newly launched drug have a history of 
suboptimal drug response or intolerance. Direct information 
on drug response was not available in data, but HbA
1c
 level 
indicated how well-regulated patients with diabetes are. From 
the measurements of HbA
1c
 at initiation, there was not much 
difference over time between initiators of GLP-1 and insulin, 
and DPP-4i initiators had lower HbA
1c
 at initiation compared 
to initiators of sulfonylurea. This indicates that patients initi-
ating the newly launched drugs had similar response profiles 
as those who initiated the established drugs. The findings in 
this study are in line with US studies comparing Sitagliptin 
(Merck & Co., Inc., Whitehouse Station, NJ, USA) with other 
oral glucose-lowering drugs where there were no changes 
in characteristics over time in the first years after launch.4–6
The use of real-world data is a necessity to investigate 
channeling bias, but it also brings along some general prob-
lems. The following potential limitations of the study were 
identified: real-world data are data of real-world patients, yet 
may suffer from missing information, which in this study was 
imputed by means of multiple imputation under the assump-
tion that the missing data are missing at random. The quality 
of real-world data may be questioned as the data seldom 
are collected primarily for research purposes. This study 
concerns a period after implementation of quality outcome 
framework in CPRD, through which the highest possible data 
quality is achieved. It was a concern that for the majority of 
patients in CPRD, body weight was measured only once, and 
that measurement was carried forward. Consequently, weight 
change will be zero for those patients. This was, however, 
not the case in the data available for this study. The risk of 
confounding is present in observational studies of the effects 
of medical treatments; this study applied propensity score 
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matching to take confounding into account. Not all relevant 
potential confounding factors are captured in the CPRD 
database (eg, diet and ethnicity), but the propensity score 
model included a diverse set of covariates describing demo-
graphics, clinical measurements, comedication including 
glucose-lowering drugs, and comorbidities. Immortal time 
bias, which is used to denote misclassification of observa-
tion time to exposure groups in survival analyses, was not 
an issue in this study since follow-up started at the first 
prescription made and was continued for the same duration 
for all subjects (ie, 180 days). However, the risk of selection 
bias in the PP cohort in this study might be an issue because 
individuals who have “survived” or stayed in the dataset at 
least 180 days were selected. However, the analyses of a PP 
cohort are relevant because our outcome measure of HbA
1c
 is 
highly affected by exposure of the investigated drugs, which 
is more likely in the PP cohort. In this study, we looked at 
drug-class levels, and combination products of sulfonylurea 
and rosiglitazone, as well as products of DPP-4i and met-
formin, were classified as sulfonylurea and DPP-4i. Change 
in characteristics over time may be affected by launch of 
specific brands and the use of monotherapy and combination 
products. Future studies may investigate channeling related 
to individual drugs. Given the size of CPRD, we decided to 
compare and match patients within time blocks of 365-day 
duration. It is possible that time blocks of shorter duration 
would reveal channeling in the very early period after launch, 
but the duration of 365 days was suitable as this will ensure 
some level of statistical power.
Studies in other medical areas have observed channeling 
bias in CPRD data. In a study comparing new nonsteroidal 
anti-inflammatory drugs (NSAIDs) with old NSAIDs on the 
risk of gastrointestinal hemorrhage, baseline characteristics 
suggested that the new NSAID population had a higher 
baseline risk (possibly explained by new NSAIDs having a 
safer profile with regard to gastrointestinal toxicity). Outcome 
analyses seemed to adjust for confounding, including chan-
neling bias, and showed a lower risk among patients treated 
with new NSAIDs.21 In the treatment of chronic obstructive 
pulmonary disease, corticosteroids have been compared 
with long-acting bronchodilators. More severe patients were 
prescribed corticosteroids, which indicated channeling. The 
adjusted analyses showed higher risk of pneumonia among 
corticosteroid users, but it was not clear to the authors if this 
was related to the effect of the drug alone, or if channeling 
bias had occurred.22
The use of a sequential cohort design, where analyses 
are done at several time points as in this study, is generally 
proposed to take channeling bias into account.23–27 Despite the 
fact that no major channeling bias was observed in this study, 
some variation over time was seen. Also, the characteristics of 
the initiators of the established drugs (basal insulin and sulfo-
nylurea) changed over time, despite the time period observed 
(2006–2015) being more or less arbitrary for these drugs. This 
generally pleads for stratifying analyses on time. The sequential 
cohort design in this study used the same propensity score 
model across time blocks, as standardized differences sug-
gested that balance across treatment groups were established 
after matching. However, individual propensity score models 
may be needed within each time block in other settings.
Conclusion
To conclude, we did not identify major channeling so that 
patients initiating the new glucose-lowering drugs differed 
importantly from patients initiating the established glucose-
lowering drugs. In this study, the differences in patient 
characteristics and changes over time were at a magnitude 
where it was still possible to estimate propensity score and 
conduct matching to control for confounding in the outcome 
analyses, even in the first year after market entry. Change in 
the characteristics of initiators of established drugs generally 
advocates for time-dependent analyses.
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